Literature DB >> 33839260

How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy.

A Fundytus1, C M Booth2, I F Tannock3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33839260     DOI： 10.1016/j.annonc.2021.03.208

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

Review 1.  Clinical Benefit Scales and Trial Design: Some Statistical Issues.

Authors:  Edward L Korn; Carmen J Allegra; Boris Freidlin
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

2.  Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

Authors:  Ziyang Mao; Xiaohui Jia; Panpan Jiang; Qinyang Wang; Yajuan Zhang; Yanlin Li; Xiaolan Fu; Min Jiao; Lili Jiang; Zhiyan Liu; Hui Guo
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

3.  A Problematic Biomarker Trial Design.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2022-02-07       Impact factor: 13.506

4.  The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis.

Authors:  Feng Li; Caichen Li; Xiuyu Cai; Zhanhong Xie; Liquan Zhou; Bo Cheng; Ran Zhong; Shan Xiong; Jianfu Li; Zhuxing Chen; Ziwen Yu; Jianxing He; Wenhua Liang
Journal:  EClinicalMedicine       Date:  2021-09-16

5.  Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.

Authors:  Mieke R Van Bockstal; Maxine Cooks; Iris Nederlof; Mariël Brinkhuis; Annemiek Dutman; Monique Koopmans; Loes Kooreman; Bert van der Vegt; Leon Verhoog; Celine Vreuls; Pieter Westenend; Marleen Kok; Paul J van Diest; Inne Nauwelaers; Nele Laudus; Carsten Denkert; David Rimm; Kalliopi P Siziopikou; Scott Ely; Dimitrios Zardavas; Mustimbo Roberts; Giuseppe Floris; Johan Hartman; Balazs Acs; Dieter Peeters; John M S Bartlett; Els Dequeker; Roberto Salgado; Fabiola Giudici; Stefan Michiels; Hugo Horlings; Carolien H M van Deurzen
Journal:  Cancers (Basel)       Date:  2021-09-29       Impact factor: 6.639

6.  Clinical research in oncology: in memory of Professor Gordon McVie.

Authors:  Ian F Tannock
Journal:  Ecancermedicalscience       Date:  2022-01-13

Review 7.  Antibody Diversity in Cancer: Translational Implications and Beyond.

Authors:  Raghuram Reddy; Joel Mintz; Roei Golan; Fakiha Firdaus; Roxana Ponce; Derek Van Booven; Aysswarya Manoharan; Isabelle Issa; Bonnie B Blomberg; Himanshu Arora
Journal:  Vaccines (Basel)       Date:  2022-07-22

Review 8.  Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors.

Authors:  Natsuki Nakagawa; Masanori Kawakami
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.